What is the current price and valuation of 2228.HK stock?

Pre-market price is **HK$9.57**. Trailing PE is **9.00** and EPS is **1.06**. Price-to-sales is **53.26** and price-to-book is **4.53**, reflecting growth premium relative to current revenue.

What catalysts should investors watch for 2228.HK stock?

Watch the earnings release on **2026-04-02**, new AI drug discovery deals, and partnership announcements. Positive trial or collaboration news can drive re-rating for 2228.HK stock.

How does Meyka AI view the near-term outlook for 2228.HK stock?

Meyka AI's forecast model projects a 12-month level of **HK$10.66** (implied +11.34%). The model also shows a quarterly target of **HK$11.76**; forecasts are model-based and not guarantees.

What are the main risks to 2228.HK stock performance?

Main risks are execution on AI drug programs, high price-to-sales multiple, long receivables (DSO **268.35**), and operating losses that could pressure near-term cash flow for 2228.HK stock.

HK Stocks

Pre-market 05 Mar 2026: XtalPi (2228.HK, HKSE) HK$9.57: AI drug discovery outlook

ByHuzaifa Zahoor March 4, 2026March 4, 2026

XtalPi (2228.HK) trades pre-market in Hong Kong at HK$9.57 on 05 Mar 2026, down -1.75% from the prior close. The 2228.HK stock shows heavy liquidity with volume 83,519,767.00 shares and a market cap of HKD 41,054,166,600.00. Fundamentals show EPS 1.06 and a trailing PE of 9.00, while technicals signal oversold conditions. We review why AI drug discovery sales cadence, cash runway and near-term catalysts matter for the HKSE-listed AI stocks theme